From the presentation given at the last AGM, and the current trend in the sp, Ambri looks as though it is on its last legs. It looks as though it needs a merger with another biotech company, or it will run out of money. Looking for partners and signing them up seems to be a priority and has been for quite a while, but no progress reports have been given since that AGM.
I was convinced the technology is good, having been exposed to it many years ago, but the commercialisation of it seems problematical now. Dow Corning were supposed to help (take the development over?) but no specific word on that line lately.
Has anybody got any further knowledge that they could update us with?
R
ABI Price at posting:
0.0¢ Sentiment: None Disclosure: Held
